Please login to the form below

Not currently logged in
Email:
Password:

MyoKardia

This page shows the latest MyoKardia news and features for those working in and with pharma, biotech and healthcare.

Sanofi bets on DiCE to find oral alternatives to injectable drugs

Sanofi bets on DiCE to find oral alternatives to injectable drugs

Other partnerships in Sanofi's Sunrise initiative include a $200m cardiomyopathy project with MyoKardia, and funding agreements with start-ups Warp Drive Bio - focusing on the use of genomics to discover

Latest news

  • Sanofi licenses cardiomyopathy programme in $200m deal Sanofi licenses cardiomyopathy programme in $200m deal

    MyoKardia's approach targets the genetic mutations that are the underlying causes of cardiomyopathy, addressing the fundamental mechanisms of the disease. ... The deal with MyoKardia has been set up under Sanofi's Sunrise initiative, which focuses on

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Pharma deals during September 2014 Pharma deals during September 2014

    One can't escape one's past. Another creative deal also with a US theme is the early stage deal between MyoKardia, a company based in California, and Sanofi. Myokardia will ... That may still be on the cards as Sanofi has made an equity investment in

  • Deal Watch table for September 2014 Deal Watch table for September 2014

    209. MyoKardia/ Sanofi. Licence and collaboration. 5. Three programmes for treatment of genetic forms of cardiomyopathy.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • MyoKardia appoints COO and medical affairs VP MyoKardia appoints COO and medical affairs VP

    California, US-based MyoKardia has appointed Dr June Lee as chief operating officer and Dr Radhika Tripuraneni as vice president of medical affairs. ... Meanwhile, Dr Tripuraneni (pictured left) brings over 10 years of medical affairs expertise in a

  • Jonathan Fox leaves AstraZeneca for MyoKardia Jonathan Fox leaves AstraZeneca for MyoKardia

    Will lead programme to target genetic heart disease. MyoKardia has appointed former VP, clinical development at AstraZeneca Jonathan Fox to chief medical officer. ... Commenting on his appointment, he highlighted MyoKardia's potential in treating genetic

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics